Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mesoblast Limited ( (AU:MSB) ) just unveiled an update.
Mesoblast Limited has notified the ASX of a proposed issue of up to 3,225,756 new warrants, to be created as a new class of securities, with a planned issue date of 23 December 2026. The warrant placement reflects an additional capital-raising avenue for the company and may provide future funding flexibility, potentially supporting its ongoing product development and commercialization activities, while modestly diluting existing shareholders if the warrants are exercised.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited, listed on the ASX under the code MSB, is a biotechnology company focused on developing and commercializing advanced cellular medicines, notably in regenerative medicine and inflammatory diseases, targeting global markets where there is significant unmet medical need.
YTD Price Performance: -6.45%
Average Trading Volume: 4,763,383
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.72B
See more data about MSB stock on TipRanks’ Stock Analysis page.